Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Ancient remedy dharasana lep tested for pain relief in small study

NCT ID NCT07085780

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a treatment called Dharasana Lep in 35 adults with mild to moderate muscle or joint pain, including rheumatoid arthritis. The goal was to see if it safely reduces pain and improves movement. Participants used the treatment and reported their pain levels using simple scales.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

35 people

The number who actually took part.

Started

Jul 2025

Finished

Sep 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

25 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Age: 25-65 years (both inclusive) at the time of consent. 2. Sex: Males and non-pregnant/non-lactating females (preferably equal number of males and females). 3. Subject is in good general health as determined by the Investigator on the basis of medical history. 4. Subject must be having presence of body ache, joint or muscle pain, sprain/strain, or back pain for more than 1 week and less than 6 months. 5. Patients must have a confirmed diagnosis of mild to moderate musculoskeletal pain and rheumatic conditions with a pain score between 4 - 7, grade will be evaluated using Visual Analog Scale (VAS). 6. Subject is able to remain on stable doses of contraceptive or replacement hormonal therapy, including no therapy, 6 weeks prior to and for the duration of the study. 7. If the subject is of childbearing potential they must have a self-reported negative urine pregnancy, is practicing and agrees to maintain an established method of birth control (IUD, hormonal implant device/injection, regular use of birth control pills or patch, diaphragm, condoms with spermicide or sponge with spermicidal jelly, cream or foam, partner vasectomy or abstinence). Females will be considered as non-childbearing potential if they are surgically sterile, have been post-menopausal for at least 1 year or have had a tubal ligation. 8. Subjects are willing to give written informed consent and are willing to follow the study procedure. 9. Subjects who commit not to use any other medicated/ prescription topical analgesics or medication, other than the test treatment for the entire duration of the study. 10. Subject is willing and able to comply with study procedures, including all scheduled visits, treatment applications, and assessments. 11. Subject is willing and able to follow the study directions, to participate in the study, returning for all specified visits. 12. Subject must be able to understand and provide written informed consent to participate in the study. Exclusion Criteria: 1. Subject has severe arthritis requiring prescription medication including immunomodulators, COX Inhibitors, etc. 2. Subjects having any skin disorder or presence of open wounds, cut, bruising, rashes etc. 3. Subjects with raw wounds, sutures, fractures and hematoma. 4. Subjects suffering from auto-immune disorder, spastic disorder, genetic disorder and any other sever traumatic conditions. 5. Subjects with chronic pain like arthritis, gout, and ankylosing spondylitis. 6. Subject have history of any hypersensitivity to the ingredients in the Lep. 7. Subject who had taken any systemic product for any illnesses for at least 3 months. 8. History of alcohol or drug addiction. 9. Pregnant or breast feeding or planning to become pregnant during the study period. 10. History of chronic illness which may influence the cutaneous state. 11. Subject have participated any clinical research study within the last 30 days.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Musculoskeletal pain are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Musculoskeletal Pain rheumatoid arthritis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • NovoBliss Research

    Ahmedabad, Gujarat, 382481, India

More trials for these conditions

Other studies related to the condition(s) this trial covers.